AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

... Drug Designation for the treatment of acute intermittent porphyria," said Sander van Deventer, ... potentially lethal disease." About Acute intermittent Porphyria Acute intermittent porphyria is a rare genetic disease in which ...

Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

... who experience the severe leg pain known as intermittent claudication. According to the PAD ... authorities as reliable indicators of efficacy in intermittent claudication clinical trials. Safety ... peak walking time and claudication onset time in intermittent claudication patients; determine the effect of ...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... new clinical-stage product -- Genasense(R) intermittent schedule completes Phase 1, heads to ... in the current calendar quarter. High-Dose intermittent Dose-Schedules: The Company has shown that high- dose, intermittent Genasense treatment was active and increased drug ...

Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference

... anti-tumor activity for XL647 administered on an intermittent schedule. Additionally, XL647 was generally well ... observed previously at the MTD (350 mg) for the intermittent dosing regimen. XL647 was generally well ... anti-tumor activity for XL647 given on an intermittent schedule in previously untreated ...

Positive Results Published Using AtriCure Minimally Invasive Products

... reported the results from 22 patients with symptomatic, drug refractory, intermittent AF who underwent a video assisted, minimally invasive, thoracoscopic ... atrial appendage was removed. Of the 22 symptomatic, drug refractory, intermittent AF patients, 8 patients presented with persistent AF and 14 patients ...

Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease

... trial, which evaluated the effect of rifalazil in the treatment of intermittent claudication, associated with peripheral arterial disease (PAD). The ... enrolled 297 consenting men and women (40-80 years old) with diagnosis of intermittent claudication due to PAD who also had high levels of antibodies to C. ...

ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting

... (Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients) is ... the ability of rifalazil to improve symptoms in patients suffering from intermittent claudication, an often debilitating and under diagnosed manifestation of ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... than are individuals who carry none. AF is the most common type of cardiac arrhythmia, and is a major risk factor for stroke. Because AF is often intermittent and difficult to detect, gauging genetic susceptibility can help doctors to decide which of their stroke patients might benefit from ...

Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients

... of about 22 degrees and expressed reduced difficulty in noticing and avoiding obstacles. On the other hand, only two patients demonstrated even an intermittent adaptation to the change in visual direction produced by the peripheral prism glasses, which means that no patient had remapped his or her brain to ...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

... made at the 2009 American Urological Association Annual Meeting in Chicago, IL. The Phase IIIB trial will investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. ...

Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production

... therapies have failed, she said ALA PDT is an excellent option that delivers dramatic results for the majority of patients. For patients with intermittent acne flares and pronounced oily skin with large pores, ALA PDT treatment with a 1450nm diode laser that heats the deep layer of skin where the oil ...

Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children

... inhibitors, which includes the FDA-approved tacrolimus ointment and pimecrolimus cream. Recently, several new studies have examined whether the intermittent use of topical calcineurin inhibitors can effectively control atopic dermatitis. In patients whose atopic dermatitis was initially controlled with ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

... REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, today announced positive results from a Phase 1 clinical study evaluating ...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... may be reinitiated at a lower dose followed by gradual dose escalation, if the clinical benefit is expected to outweigh potential risks. intermittent proteinuria (urine protein/creatinine ratio >0.6 mg/mg) occurred in 18.6% of Exjade-treated patients, compared to 7.2% of deferoxamine-treated ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... Symptoms of RA include joint stiffness, joint pain, inflammation of the affected areas and an associated reduction in mobility. These symptoms can be intermittent and vary in severity from patient to patient. In more severe cases RA can eventually lead to disability. RA patients are also at a higher risk of ...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... can cause thromboses (blood clots), disabling fatigue, anemia, impaired quality of life, shortness of breath, recurrent pain, kidney disease and intermittent episodes of dark-colored urine (hemoglobinuria). (2-4) Soliris, Hemolysis and Fatigue in PNH Fatigue levels in patients with PNH are often severe ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594

... crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and ...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

... kidney disease, liver dysfunction, disabling fatigue, impaired quality of life, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), and anemia. (2-4) Clinical Data In the ongoing open-label clinical study, investigators examined ...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... kidney disease, liver dysfunction, disabling fatigue, impaired quality of life, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), and anemia.(1-3) Impaired kidney function is common among patients with PNH, (4-8) and kidney ...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

... kidney disease, liver dysfunction, disabling fatigue, impaired quality of life, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), and anemia.(1-3) Efficacy in a Broader Population "The data from the SHEPHERD study confirm the ...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

... Symptoms of RA include joint stiffness, joint pain, inflammation of the affected areas and an associated reduction in mobility. These symptoms can be intermittent and vary in severity from patient to patient. In more severe cases RA can eventually lead to disability. RA patients are also at a higher risk of ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... hemolysis. In patients with PNH, hemolysis can cause severe anemia, disabling fatigue, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), kidney disease, impaired quality of life and thromboses. (1,2) "Thrombosis is the leading cause of ...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

... data on its AMT-020 gene therapy to treat acute intermittent porphyria (AIP) at the Porphyrins and Porphyrias ... > . About Acute intermittent Porphyria Acute intermittent porphyria is a life threatening inherited disease ...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

... showed that peak and average concentrations over 28 days were higher with intermittent compared with daily dosing of XL880, reflecting the higher dose administered with the intermittent schedule, and the compound's long half life. The data indicate that ...